Drugs / HIV-1 recombinant Ad5 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01054872 | Jan 2010 → Nov 2012 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIV-1 recombinant Ad5 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01054872 ↗ |
| Modality | Vaccine | “recombinant adenoviral serotype 5 (rAd5) vector HIV vaccine” NCT01054872 ↗ |
| Route | Intramuscular | “1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid” NCT01054872 ↗ |